Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Annovis is conducting a clinical study to investigate Posiphen in patients with Early
Alzheimer's Disease (AD) and Early Parkinson's Disease (PD). Investigators are looking to
recruit 68 patients in two parts of the study. In Part one of the study Investigators will
recruit 14 AD and 14 PD patients who will either receive placebo (an inert pill which looks
like the study drug) or the study drug Posiphen, both taken daily. In Part two of the study
Investigators will recruit 40 PD patients who will receive different strengths of the study
drug Posiphen taken daily. Patients will be required to come to the site for 3 face to face
visits and have 4 phone calls, tests include but are not limited to, blood and CSF (spinal
fluid) sampling, cognitive assessments, clinical examinations and laboratory safety tests.
Primarily the Investigators are looking for the safety and tolerability of Posiphen, although
Investigators will also evaluate the activity of Posiphen by a number of different biomarkers
measuring pathway and target engagements.